시장보고서
상품코드
1301470

장기이식 거부반응 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2022-2031년)

Organ Transplant Rejection Medication Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 241 Pages | 배송안내 : 2-10일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

장기이식 거부반응 치료제 시장 - 보고서의 범위

TMR의 세계 장기이식 거부반응 치료제 시장에 대한 보고서는 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회도 조사했습니다. 이 보고서는 2023년을 기준연도로, 2031년을 예측연도로 하여 2017년부터 2031년까지의 세계 장기이식 거부반응 치료제 시장의 수익을 예측했습니다. 또한 2023-2031년간 세계 장기이식 거부반응 치료제 시장의 연평균 성장률(CAGR%)도 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 분석가들이 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하여 주요 조사 활동의 대부분을 수행했으며, 2차 조사에서는 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조를 통해 장기이식 거부반응 치료제 시장을 파악했습니다.

이 보고서는 세계 장기이식 거부반응 치료제 시장 경쟁 구도를 자세히 분석합니다. 세계 장기이식 거부 반응 약물 시장에서 활동하는 주요 기업이 식별되며, 이들 각각은 다양한 속성 측면에서 프로파일링됩니다. 기업 프로파일, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 장기이식 거부 반응 약물 시장 기업의 속성입니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 서론
  • 개요
  • 시장 역학
  • 세계 시장 분석과 예측, 2017-2031년

제5장 주요 인사이트

  • 현재 세계의 시나리오 : 이식을 위한 장기 제공
  • 주요 제품/브랜드 분석
  • 파이프라인 분석
  • COVID-19의 영향 분석

제6장 세계 시장 분석과 예측 : 의약품 클래스별

  • 서론과 정의
  • 주요 발견/개발
  • 시장 매출 예측 : 의약품 클래스별, 2017-2031
    • 항체
      • Thymoglobulin
      • Alemtuzumab
      • Belatacept
      • Muromonab-CD3
      • Basiliximab
      • Eculizumab
    • 대사 길항 물질
      • Azathioprine
      • Mycophenolate Mofetil
      • Mycophenolate sodium, MPA
    • 칼시뉴린 저해제
      • Cyclosporine
      • Tacrolimus
    • mTOR 저해제
      • Sirolimus
      • Everolimus
    • 스테로이드
      • Prednisolone
      • Methylprednisolone
  • 시장 매력 분석 : 의약품 클래스별

제7장 세계 시장 분석과 예측 : 이식 유형별

  • 서론과 정의
  • 주요 발견/개발
  • 시장 매출 예측 : 이식 유형별, 2017-2031
    • 신장
    • 심장
    • 췌장
    • 기타
  • 시장 매력 분석 : 이식 유형별

제8장 세계 시장 분석과 예측 : 유통 채널별

  • 서론과 정의
  • 주요 발견/개발
  • 시장 매출 예측 : 유통 채널별, 2017-2031
    • 병원 약국
    • 소매 약국
    • 온라인 약국
  • 시장 매력 분석 : 유통 채널별

제9장 세계 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 매출 예측 : 지역별, 2017-2031
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 분석 : 지역별

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 예측

제14장 중동 및 아프리카 시장 분석과 예측

제15장 경쟁 구도

  • 시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
  • 시장 점유율 분석 : 기업별(2022년)
  • 기업 개요
    • Pfizer, Inc.
    • Astellas Pharma, Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc
    • AbbVie, Inc.
    • Hansa Biopharma
    • WOCKHARDT
    • Viatris, Inc.
    • Glenmark
    • Biocon
    • Hikma Pharmaceuticals plc
    • Teva Pharmaceutical USA Inc.
    • Zydus Pharmaceuticals, Inc.
LSH 23.07.13

Organ Transplant Rejection Medication Market - Scope of Report

TMR's report on the global Organ Transplant Rejection Medication market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Organ Transplant Rejection Medication market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Organ Transplant Rejection Medication market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Organ Transplant Rejection Medication market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Organ Transplant Rejection Medication market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Organ Transplant Rejection Medication market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Organ Transplant Rejection Medication market.

The report delves into the competitive landscape of the global Organ Transplant Rejection Medication market. Key players operating in the global Organ Transplant Rejection Medication market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Organ Transplant Rejection Medication market profiled in this report.

Key Questions Answered in Global Organ Transplant Rejection Medication Market Report:

  • What is the sales/revenue generated by Organ Transplant Rejection Medication across all regions during the forecast period?
  • What are the opportunities in the global Organ Transplant Rejection Medication market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Organ Transplant Rejection Medication Market - Research Objectives and Research Approach

The comprehensive report on the global Organ Transplant Rejection Medication market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Organ Transplant Rejection Medication market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Organ Transplant Rejection Medication market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Organ Transplant Rejection Medication Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Organ Transplant Rejection Medication Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Current Global Scenario: Organ Donation for Transplantation
  • 5.2. Key Product/Brand Analysis
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Impact Analysis

6. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Antibodies
      • 6.3.1.1. Thymoglobulin
      • 6.3.1.2. Alemtuzumab
      • 6.3.1.3. Belatacept
      • 6.3.1.4. Muromonab-CD3
      • 6.3.1.5. Basiliximab
      • 6.3.1.6. Eculizumab
    • 6.3.2. Antimetabolites
      • 6.3.2.1. Azathioprine
      • 6.3.2.2. Mycophenolate Mofetil
      • 6.3.2.3. Mycophenolate sodium, MPA
    • 6.3.3. Calcineurin Inhibitors
      • 6.3.3.1. Cyclosporine
      • 6.3.3.2. Tacrolimus
    • 6.3.4. mTOR Inhibitors
      • 6.3.4.1. Sirolimus
      • 6.3.4.2. Everolimus
    • 6.3.5. Steroids
      • 6.3.5.1. Prednisolone
      • 6.3.5.2. Methylprednisolone
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Transplant Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 7.3.1. Kidney
    • 7.3.2. Liver
    • 7.3.3. Heart
    • 7.3.4. Lung
    • 7.3.5. Pancreas
    • 7.3.6. Others
  • 7.4. Market Attractiveness Analysis, by Transplant Type

8. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Organ Transplant Rejection Medication Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. Antibodies
      • 10.2.1.1. Thymoglobulin
      • 10.2.1.2. Alemtuzumab
      • 10.2.1.3. Belatacept
      • 10.2.1.4. Muromonab-CD3
      • 10.2.1.5. Basiliximab
      • 10.2.1.6. Eculizumab
    • 10.2.2. Antimetabolites
      • 10.2.2.1. Azathioprine
      • 10.2.2.2. Mycophenolate Mofetil
      • 10.2.2.3. Mycophenolate sodium, MPA
    • 10.2.3. Calcineurin Inhibitors
      • 10.2.3.1. Cyclosporine
      • 10.2.3.2. Tacrolimus
    • 10.2.4. mTOR Inhibitors
      • 10.2.4.1. Sirolimus
      • 10.2.4.2. Everolimus
    • 10.2.5. Steroids
      • 10.2.5.1. Prednisolone
      • 10.2.5.2. Methylprednisolone
  • 10.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 10.3.1. Kidney
    • 10.3.2. Liver
    • 10.3.3. Heart
    • 10.3.4. Lung
    • 10.3.5. Pancreas
    • 10.3.6. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Transplant Type
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Organ Transplant Rejection Medication Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Antibodies
      • 11.2.1.1. Thymoglobulin
      • 11.2.1.2. Alemtuzumab
      • 11.2.1.3. Belatacept
      • 11.2.1.4. Muromonab-CD3
      • 11.2.1.5. Basiliximab
      • 11.2.1.6. Eculizumab
    • 11.2.2. Antimetabolites
      • 11.2.2.1. Azathioprine
      • 11.2.2.2. Mycophenolate Mofetil
      • 11.2.2.3. Mycophenolate sodium, MPA
    • 11.2.3. Calcineurin Inhibitors
      • 11.2.3.1. Cyclosporine
      • 11.2.3.2. Tacrolimus
    • 11.2.4. mTOR Inhibitors
      • 11.2.4.1. Sirolimus
      • 11.2.4.2. Everolimus
    • 11.2.5. Steroids
      • 11.2.5.1. Prednisolone
      • 11.2.5.2. Methylprednisolone
  • 11.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 11.3.1. Kidney
    • 11.3.2. Liver
    • 11.3.3. Heart
    • 11.3.4. Lung
    • 11.3.5. Pancreas
    • 11.3.6. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Transplant Type
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Organ Transplant Rejection Medication Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Antibodies
      • 12.2.1.1. Thymoglobulin
      • 12.2.1.2. Alemtuzumab
      • 12.2.1.3. Belatacept
      • 12.2.1.4. Muromonab-CD3
      • 12.2.1.5. Basiliximab
      • 12.2.1.6. Eculizumab
    • 12.2.2. Antimetabolites
      • 12.2.2.1. Azathioprine
      • 12.2.2.2. Mycophenolate Mofetil
      • 12.2.2.3. Mycophenolate sodium, MPA
    • 12.2.3. Calcineurin Inhibitors
      • 12.2.3.1. Cyclosporine
      • 12.2.3.2. Tacrolimus
    • 12.2.4. mTOR Inhibitors
      • 12.2.4.1. Sirolimus
      • 12.2.4.2. Everolimus
    • 12.2.5. Steroids
      • 12.2.5.1. Prednisolone
      • 12.2.5.2. Methylprednisolone
  • 12.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 12.3.1. Kidney
    • 12.3.2. Liver
    • 12.3.3. Heart
    • 12.3.4. Lung
    • 12.3.5. Pancreas
    • 12.3.6. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Transplant Type
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Organ Transplant Rejection Medication Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Antibodies
      • 13.2.1.1. Thymoglobulin
      • 13.2.1.2. Alemtuzumab
      • 13.2.1.3. Belatacept
      • 13.2.1.4. Muromonab-CD3
      • 13.2.1.5. Basiliximab
      • 13.2.1.6. Eculizumab
    • 13.2.2. Antimetabolites
      • 13.2.2.1. Azathioprine
      • 13.2.2.2. Mycophenolate Mofetil
      • 13.2.2.3. Mycophenolate sodium, MPA
    • 13.2.3. Calcineurin Inhibitors
      • 13.2.3.1. Cyclosporine
      • 13.2.3.2. Tacrolimus
    • 13.2.4. mTOR Inhibitors
      • 13.2.4.1. Sirolimus
      • 13.2.4.2. Everolimus
    • 13.2.5. Steroids
      • 13.2.5.1. Prednisolone
      • 13.2.5.2. Methylprednisolone
  • 13.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 13.3.1. Kidney
    • 13.3.2. Liver
    • 13.3.3. Heart
    • 13.3.4. Lung
    • 13.3.5. Pancreas
    • 13.3.6. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Transplant Type
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Organ Transplant Rejection Medication Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Antibodies
      • 14.2.1.1. Thymoglobulin
      • 14.2.1.2. Alemtuzumab
      • 14.2.1.3. Belatacept
      • 14.2.1.4. Muromonab-CD3
      • 14.2.1.5. Basiliximab
      • 14.2.1.6. Eculizumab
    • 14.2.2. Antimetabolites
      • 14.2.2.1. Azathioprine
      • 14.2.2.2. Mycophenolate Mofetil
      • 14.2.2.3. Mycophenolate sodium, MPA
    • 14.2.3. Calcineurin Inhibitors
      • 14.2.3.1. Cyclosporine
      • 14.2.3.2. Tacrolimus
    • 14.2.4. mTOR Inhibitors
      • 14.2.4.1. Sirolimus
      • 14.2.4.2. Everolimus
    • 14.2.5. Steroids
      • 14.2.5.1. Prednisolone
      • 14.2.5.2. Methylprednisolone
  • 14.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 14.3.1. Kidney
    • 14.3.2. Liver
    • 14.3.3. Heart
    • 14.3.4. Lung
    • 14.3.5. Pancreas
    • 14.3.6. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Transplant Type
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer, Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Astellas Pharma, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Novartis AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. F. Hoffmann-La Roche Ltd.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Sanofi
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. GlaxoSmithKline plc
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. AbbVie, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Hansa Biopharma
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. WOCKHARDT
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Business Strategies
      • 15.3.10.4. Recent Developments
    • 15.3.11. Viatris, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments
    • 15.3.12. Glenmark
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Product Portfolio
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Developments
    • 15.3.13. Biocon
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Financial Overview
      • 15.3.13.3. Product Portfolio
      • 15.3.13.4. Business Strategies
      • 15.3.13.5. Recent Developments
    • 15.3.14. Hikma Pharmaceuticals plc
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Financial Overview
      • 15.3.14.3. Product Portfolio
      • 15.3.14.4. Business Strategies
      • 15.3.14.5. Recent Developments
    • 15.3.15. Teva Pharmaceutical U.S.A Inc.
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Financial Overview
      • 15.3.15.3. Product Portfolio
      • 15.3.15.4. Business Strategies
      • 15.3.15.5. Recent Developments
    • 15.3.16. Zydus Pharmaceuticals, Inc.
      • 15.3.16.1. Company Overview
      • 15.3.16.2. Financial Overview
      • 15.3.16.3. Product Portfolio
      • 15.3.16.4. Business Strategies
      • 15.3.16.5. Recent Developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제